Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) FCF Margin (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of FCF Margin data on record, last reported at 8.55% in Q4 2025.

  • For Q4 2025, FCF Margin rose 4423.0% year-over-year to 8.55%; the TTM value through Dec 2025 reached 4.94%, up 4130.0%, while the annual FY2025 figure was 4.94%, 4130.0% up from the prior year.
  • FCF Margin reached 8.55% in Q4 2025 per TARS's latest filing, down from 13.77% in the prior quarter.
  • Across five years, FCF Margin topped out at 588.95% in Q3 2021 and bottomed at 3759.47% in Q4 2021.
  • Average FCF Margin over 5 years is 516.92%, with a median of 35.48% recorded in 2021.
  • The widest YoY moves for FCF Margin: up 365431bps in 2022, down -283059bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 3759.47% in 2021, then soared by 97bps to 105.16% in 2022, then tumbled by -176bps to 290.36% in 2023, then surged by 88bps to 35.67% in 2024, then surged by 124bps to 8.55% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 8.55% in Q4 2025, 13.77% in Q3 2025, and 30.14% in Q2 2025.